CY1122305T1 - Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc - Google Patents

Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc

Info

Publication number
CY1122305T1
CY1122305T1 CY20191101181T CY191101181T CY1122305T1 CY 1122305 T1 CY1122305 T1 CY 1122305T1 CY 20191101181 T CY20191101181 T CY 20191101181T CY 191101181 T CY191101181 T CY 191101181T CY 1122305 T1 CY1122305 T1 CY 1122305T1
Authority
CY
Cyprus
Prior art keywords
compounds
hydroxazole
hydroxamic acid
lpxc inhibitors
lpxc
Prior art date
Application number
CY20191101181T
Other languages
English (en)
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume LAPOINTE
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122305T1 publication Critical patent/CY1122305T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Αυτή η εφεύρεση σχετίζεται γενικά με ενώσεις με Τύπο I όπως περιγράφεται στο παρόν και συνθέσεις που περιέχουν αυτές τις ενώσεις, όπως επίσης και μεθόδους χρησιμοποίησης αυτών των ενώσεων για αντιμετώπιση βακτηριακών λοιμώξεων. Σε ορισμένα θέματα, η εφεύρεση παρέχει μεθόδους και συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις για αντιμετώπιση λοιμώξεων που προκαλούνται από αρνητικά κατά Gram βακτήρια.
CY20191101181T 2014-12-16 2019-11-11 Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc CY1122305T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (en) 2014-12-16 2015-12-15 Isoxazole hydroxamic acid compounds as lpxc inhibitors

Publications (1)

Publication Number Publication Date
CY1122305T1 true CY1122305T1 (el) 2021-01-27

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101181T CY1122305T1 (el) 2014-12-16 2019-11-11 Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc

Country Status (41)

Country Link
US (3) US9549916B2 (el)
EP (1) EP3233843B1 (el)
JP (1) JP6697466B2 (el)
KR (1) KR20170094214A (el)
CN (1) CN107001295B (el)
AR (1) AR107428A1 (el)
AU (1) AU2015365455B2 (el)
BR (1) BR112017011422A2 (el)
CA (1) CA2969803A1 (el)
CL (1) CL2017001460A1 (el)
CO (1) CO2017005870A2 (el)
CR (1) CR20170260A (el)
CU (1) CU24443B1 (el)
CY (1) CY1122305T1 (el)
DK (1) DK3233843T3 (el)
EA (1) EA032138B1 (el)
EC (1) ECSP17045737A (el)
ES (1) ES2756300T3 (el)
GT (1) GT201700132A (el)
HR (1) HRP20192009T1 (el)
HU (1) HUE047225T2 (el)
IL (1) IL252373B (el)
JO (1) JO3818B1 (el)
LT (1) LT3233843T (el)
MA (1) MA41185B1 (el)
ME (1) ME03546B (el)
MX (1) MX2017007980A (el)
MY (1) MY195743A (el)
PE (1) PE20171044A1 (el)
PH (1) PH12017501019B1 (el)
PL (1) PL3233843T3 (el)
PT (1) PT3233843T (el)
RS (1) RS59507B1 (el)
SG (1) SG11201704053WA (el)
SI (1) SI3233843T1 (el)
SV (1) SV2017005462A (el)
TN (1) TN2017000207A1 (el)
TW (1) TWI693215B (el)
UA (1) UA121225C2 (el)
UY (1) UY36448A (el)
WO (1) WO2016097995A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201905814T4 (tr) 2013-05-17 2019-05-21 Incyte Corp Jak inhibitörü olarak bipirazol tuzu.
CA3026356A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JPWO2020105660A1 (ja) * 2018-11-21 2021-09-30 大正製薬株式会社 新規イミダゾール誘導体
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
CN117279898A (zh) * 2021-02-11 2023-12-22 布莱克史密斯医药公司 抗菌化合物
AR124841A1 (es) * 2021-02-11 2023-05-10 Forge Therapeutics Inc Compuestos antibacterianos
TW202322818A (zh) * 2021-09-28 2023-06-16 美商福吉醫療公司 Lpxc抑制劑及其用途
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途
WO2024067813A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和其医药上的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
EP0418667B1 (de) 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carbonsäureamide
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CN1777577B (zh) * 2003-01-08 2011-07-06 诺华疫苗和诊断公司 抗菌剂
CA2525717A1 (en) 2003-05-23 2004-12-09 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
MX2011000039A (es) 2008-07-02 2011-05-31 Emergent Product Dev Seattle Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
EP2334636A2 (en) * 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
EP2488489A2 (en) * 2009-10-13 2012-08-22 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2782453C (en) * 2009-12-16 2015-11-24 Matthew Frank Brown N-linked hydroxamic acid derivatives useful as antibacterial agents
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013011693A2 (pt) 2010-11-10 2016-08-09 Achaogen Inc derivados de ácido hidroxâmico e seu uso no tratamento de infecções por bactérias
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
CA2830920C (en) * 2011-04-08 2015-07-14 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
PH12017501019A1 (en) 2017-12-04
AU2015365455A1 (en) 2017-06-08
CO2017005870A2 (es) 2017-10-20
PL3233843T3 (pl) 2020-04-30
TN2017000207A1 (en) 2018-10-19
US10029994B2 (en) 2018-07-24
US9549916B2 (en) 2017-01-24
UY36448A (es) 2016-07-29
IL252373A0 (en) 2017-07-31
MX2017007980A (es) 2017-09-29
JP6697466B2 (ja) 2020-05-20
JP2018500333A (ja) 2018-01-11
US20160166548A1 (en) 2016-06-16
WO2016097995A1 (en) 2016-06-23
EA201791353A1 (ru) 2017-10-31
US20170088525A1 (en) 2017-03-30
ME03546B (me) 2020-07-20
TW201629024A (zh) 2016-08-16
US20180030004A1 (en) 2018-02-01
TWI693215B (zh) 2020-05-11
ECSP17045737A (es) 2019-02-28
AU2015365455B2 (en) 2019-01-17
HRP20192009T1 (hr) 2020-02-07
CN107001295B (zh) 2021-02-02
CL2017001460A1 (es) 2017-12-22
US9815804B2 (en) 2017-11-14
IL252373B (en) 2019-11-28
JO3818B1 (ar) 2021-01-31
PT3233843T (pt) 2019-11-26
EA032138B1 (ru) 2019-04-30
DK3233843T3 (da) 2019-11-18
CA2969803A1 (en) 2016-06-23
GT201700132A (es) 2019-10-10
LT3233843T (lt) 2019-12-10
KR20170094214A (ko) 2017-08-17
EP3233843A1 (en) 2017-10-25
PE20171044A1 (es) 2017-07-19
UA121225C2 (uk) 2020-04-27
BR112017011422A2 (pt) 2018-04-03
PH12017501019B1 (en) 2017-12-04
SI3233843T1 (sl) 2019-12-31
CR20170260A (es) 2017-08-21
EP3233843B1 (en) 2019-10-16
ES2756300T3 (es) 2020-04-27
SV2017005462A (es) 2018-04-04
HUE047225T2 (hu) 2020-04-28
SG11201704053WA (en) 2017-06-29
CN107001295A (zh) 2017-08-01
AR107428A1 (es) 2018-05-02
MA41185B1 (fr) 2019-12-31
MY195743A (en) 2023-02-08
CU20170084A7 (es) 2017-11-07
RS59507B1 (sr) 2019-12-31
CU24443B1 (es) 2019-10-04

Similar Documents

Publication Publication Date Title
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
EA201691534A1 (ru) Лечение устойчивых угрей
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
BR112015032595A2 (pt) inibidores de ido
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201491970A1 (ru) Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
EA201690844A1 (ru) Ингибиторы gsk-3
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
MX2017012073A (es) Compuestos de minociclina para biodefensas.
CR20170050A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
EA201590331A1 (ru) Новые антибактериальные соединения
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201590729A1 (ru) Производные 3,4-дизамещенного оксазолидинона и их применение в качестве ингибиторов кальцийактивируемых калиевых каналов
CY1119316T1 (el) Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
EA202090336A1 (ru) Соединения, их соли и способы лечения заболеваний